Quantum BioPharma (NASDAQ: QNTM) disclosed the results of its November 10, 2026, annual general and special meeting and the closing of a non-brokered private placement of 26 Class A multiple voting shares on November 9. The placement, priced at C$3.11 per share for gross proceeds of C$80.86, was acquired by entities tied to CEO Zeeshan Saeed and director Anthony Durkacz. The Xorax Family Trust, associated with Saeed, and Fortius Research and Trading Corp., controlled by Durkacz, each purchased 13 shares.
The small dollar figure understates the transaction's significance. Because Class A multiple voting shares carry disproportionate voting rights, the issuance increased the aggregate voting power of that class from approximately 57.01% to 68.22%. That means insiders now command a supermajority of voting influence, a level that can effectively determine the outcome of most shareholder votes. The company completed the placement under shareholder authorization granted in 2025, with proceeds designated for general working capital.
At the meeting, shareholders elected all five director nominees, reappointed MNP LLP as auditor and approved several resolutions. These included authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power, a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1 and a potential corporate name change. The board retains discretion over whether and when to implement these measures.
The combination of expanded insider voting control and the authorization to issue more multiple voting shares up to a 70% threshold is notable because it gives management and affiliated holders significant flexibility to preserve their dominance. A share consolidation, if implemented, could also affect the company's share price and market structure, though the board has not committed to acting. For investors, the concentration of voting power may reduce the practical influence of common shareholders over governance decisions. Further details are available in the full release at https://ibn.fm/UagXR, and ongoing updates relating to QNTM can be found in the company's newsroom at https://ibn.fm/QNTM.
Quantum BioPharma describes itself as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse. Its lead compound, Lucid-MS, is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The company also invented UNBUZZD and retains a 19.84% ownership stake in Unbuzzd Wellness Inc. as of March 31, 2026, along with royalty rights on sales. The original release is accessible through www.newmediawire.com.
